Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Acta Neurol Scand ; 79(6): 493-9, 1989 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-2476906

RESUMO

Two patients with Parkinson's disease were treated with 1 g tetrahydrobiopterin (BH4) for 5 days. Clinical improvement was not observed. In the cerebrospinal fluid (CSF) a 4-8 fold increase in the concentration of homovanillic acid (HVA), and a 3-fold increase in the concentration of 5-hydroxyindole acetic acid (5-HIAA) was measured. However, the concentration of HVA reached, was only approximately half as high, as that of patients treated with madopar (DOPA + benserazid). In urine, the excretion of HVA increased 13-37 fold, when the patients were treated with madopar, whereas no increase in the HVA excretion was measured after the BH4 administration. Additionally, 2 patients with Parkinson's disease were treated with 1 g BH4 in combination with 15 g tyrosine for 3 days, and 1 parkinsonian patient was treated with 15 g tyrosine daily for 7 weeks. No increase in the CSF concentrations of HVA or 5-HIAA was observed. The results suggest, the BH4 in the dosage used, is not effective in the treatment of Parkinson's disease.


Assuntos
Biopterinas/análogos & derivados , Doença de Parkinson/tratamento farmacológico , Adulto , Antiparkinsonianos/uso terapêutico , Benserazida/uso terapêutico , Biopterinas/uso terapêutico , Ensaios Clínicos como Assunto , Combinação de Medicamentos/uso terapêutico , Ácido Homovanílico/líquido cefalorraquidiano , Ácido Homovanílico/urina , Humanos , Ácido Hidroxi-Indolacético/líquido cefalorraquidiano , Ácido Hidroxi-Indolacético/urina , Levodopa/uso terapêutico , Masculino , Pessoa de Meia-Idade , Tirosina/sangue , Tirosina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...